Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Breast Cancer Res Treat. 2011 Sep 3;131(2):571–580. doi: 10.1007/s10549-011-1743-4

Table 3.

Rate ratios and 95% confidence intervals for BMI and CBC risk stratified by menopausal status and ER status of the first primary tumor

Cases (CBC)
 Controls (UBC)
 RRa 95% CI P for trendb
N % N %
Premenopausal
    ER positive
        <25 86 79.6 147 76.6 1.00 0.85
        25 to <30 15 13.9 30 15.6 0.86 0.41, 1.82
        ≥30 7 6.5 15 7.8 0.86 0.29, 2.58
    ER negative
        <25 43 64.2 71 66.4 1.00 0.26
        25 to <30 14 20.9 29 27.1 1.02 0.44, 2.35
        ≥30 10 14.9 7 6.5 2.68 0.79, 9.11
Postmenopausal
    ER positive
        <25 94 69.1 206 65.0 1.00 0.40
        25 to <30 25 18.4 80 25.2 0.71 0.38, 1.32
        ≥30 17 12.5 31 9.8 0.94 0.39, 2.30
    ER negative
        <25 43 59.7 98 67.6 1.00 0.30
        25 to <30 17 23.6 38 26.2 0.51 0.22, 1.17
        ≥30 12 16.7 9 6.2 5.64 1.76, 18.13

CBC asynchronous contralateral breast cancer, UBC unilateral breast cancer, BMI body mass index (kg/m2), RR rate ratio, CI confidence interval, ER estrogen receptor

a

Adjusted for age at first diagnosis, age at menarche, number of pregnancies, family history, histology, stage, chemotherapy, hormonal treatment, and radiation treatment

b

P-value for a linear trend across BMI categories